Loading...
Loading...

The limits of knowing coronary artery disease anatomy, fish oil and AF risk, a new drug for PSVT, and maybe I was wrong about a drug for AF conversion (the RAFF4 trial). These are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Prediction of CAD is hard — even if you have anatomy
II Fish Oil and AF (and as a bonus we learn again about analytic flexibility)
https://www.medscape.com/viewarticle/995290
III A New Drug for PSVT
IV AF Conversion with Vernakalant
VI A Quick Note on HFpEF
Med Op-Ed: Avalanche Survival, HFpEF Skepticism, and More
https://www.medscape.com/viewarticle/med-op-ed-avalanche-survival-hfpef-skepticism-and-more-2026a1000012
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
No transcript available for this episode.